Bladder cancer combo shows promise in Real-World review
NCT ID NCT07420855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at how well a combination of two drugs—enfortumab vedotin and pembrolizumab—works as the first treatment for people with advanced bladder cancer that has spread. Researchers will collect data from 361 patients around the world to see how long they live and how the cancer responds. The goal is to learn from real-world experience, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enfortumab vedotin plus pembrolizumab
- What this could lead to
- If successful, this study could confirm that this drug combination works well as a first treatment for advanced bladder cancer, potentially improving survival and guiding future standard care.
- What could go wrong
- This is a retrospective study, meaning it looks back at past treatments rather than testing a new approach. Results may be less reliable than a controlled trial, and the combination can cause serious side effects like immune reactions or nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ospedale di Macerata
Province of Macerata, 62100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral drug targets Cancer's growth engine in advanced tumours
- Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
- New drug combo aims to tackle Hard-to-Treat HER2 cancers
- New drug YH32364 targets Hard-to-Treat cancers in first human trial
- New drug cocktail aims to outperform chemo for advanced bladder cancer
- New drug combo may help bladder cancer patients keep their bladder